Review of applications of CRISPR-Cas9 gene-editing technology in cancer research
Open Access
- 15 July 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Biological Procedures Online
- Vol. 23 (1), 1-13
- https://doi.org/10.1186/s12575-021-00151-x
Abstract
Characterized by multiple complex mutations, including activation by oncogenes and inhibition by tumor suppressors, cancer is one of the leading causes of death. Application of CRISPR-Cas9 gene-editing technology in cancer research has aroused great interest, promoting the exploration of the molecular mechanism of cancer progression and development of precise therapy. CRISPR-Cas9 gene-editing technology provides a solid basis for identifying driver and passenger mutations in cancer genomes, which is of great value in genetic screening and for developing cancer models and treatments. This article reviews the current applications of CRISPR-Cas9 gene-editing technology in various cancer studies, the challenges faced, and the existing solutions, highlighting the potential of this technology for cancer treatment.Keywords
This publication has 105 references indexed in Scilit:
- Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas systemNucleic Acids Research, 2013
- Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene ExpressionCell, 2013
- RNA-Guided Human Genome Engineering via Cas9Science, 2013
- Multiplex Genome Engineering Using CRISPR/Cas SystemsScience, 2013
- A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial ImmunityScience, 2012
- Genome editing with engineered zinc finger nucleasesNature Reviews Genetics, 2010
- Effect of Genome Size on AAV Vector PackagingMolecular Therapy, 2010
- Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivoJournal of Hepatology, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Assembly and function of RNA silencing complexesNature Reviews Molecular Cell Biology, 2005